S-1/A: PACS Group Files Amendment for IPO, Aiming to List on NYSE

PACS Group, a leading post-acute healthcare company, has filed an amendment to its S-1 registration statement for an initial public offering of 19,050,000 shares of common stock, with plans to list on the NYSE under the symbol PACS.

Summary

• PACS Group, Inc. has filed an amendment to its Form S-1 registration statement with the SEC for its initial public offering.
• The company plans to offer 19,050,000 shares of its common stock to the public.
• The anticipated initial public offering price is estimated to be between $20.00 and $22.00 per share.
• PACS Group has applied to list its common stock on the New York Stock Exchange (NYSE) under the ticker symbol PACS.
• The underwriters have been granted a 30-day option to purchase up to 2,857,500 additional shares from the selling stockholders.
• Following the offering, the founders will collectively own a significant majority of the common stock, representing approximately 87.1% of the voting power.
• The founders will have the right to designate four directors, which represents the entirety of the current four member board of directors.
• The company intends to use approximately $330.0 million of the net proceeds from this offering to repay a portion of the amounts outstanding under its Amended and Restated 2023 Credit Facility.
• PACS Group is a controlled company within the meaning of the NYSE corporate governance standards and intends to rely on exemptions from certain corporate governance standards.
• The underwriters expect to deliver the shares of common stock to purchasers on or about , 2024.

Sentiment

Score: 6

Explanation: The document is largely factual and descriptive, outlining the terms of the IPO and providing background information on the company. While there are positive aspects highlighted, the presence of risk factors and the discussion of debt repayment temper the overall sentiment.

Positives

• The company is using a significant portion of the IPO proceeds to reduce its debt.
• The company has a comprehensive suite of technology, support, and back-office services that allow local leadership teams to focus more of their time and effort on providing quality care to patients.

Negatives

• Founders will retain significant control, potentially limiting other stockholders' influence.
• The company will be a controlled company and intends to rely on exemptions from certain corporate governance standards of the NYSE.
• The company will have broad discretion in how it may use the net proceeds from this offering, and it may not use them effectively.

Risks

• Investing in the company's common stock involves risks, as detailed in the Risk Factors section of the prospectus.
• The company depends upon reimbursement from third-party payors, and its revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in its facilities as well as changes in payor mix and payment methodologies and new cost containment initiatives by third-party payors.
• The company may not be fully reimbursed for all services for which each facility bills through consolidated billing or bundled payments, which could have an adverse effect on its revenue, financial condition and results of operations.
• Increased competition for, or a shortage of, nurses, nurse assistants and other skilled personnel could increase the company's staffing and labor costs and subject it to monetary fines.
• The company relies on payments from third-party payors, including Medicare, Medicaid and other governmental healthcare programs and private insurance organizations.
• Reforms to the U.S. healthcare system, including new regulations under the Affordable Care Act (ACA), continue to impose new requirements upon the company that could materially impact its business.
• The company is subject to various government and third-party payor reviews, audits and investigations that could adversely affect its business, including an obligation to refund amounts previously paid to it, potential criminal charges, the imposition of fines, and/or the loss of its right to participate in Medicare and Medicaid programs or other third-party payor programs.
• State efforts to regulate or deregulate the healthcare services industry or the construction expansion, or acquisition of healthcare facilities could impair the company's ability to expand its operations, or could result in increased competition.
• The company faces numerous risks related to expiration of the COVID19 public health emergency (PHE) expiration and surrounding wind down and uncertainty, which could, individually or in the aggregate, have a material adverse effect on its business, financial condition, liquidity, results of operations and prospects.
• If the company fails to attract patients and residents and to compete effectively with other healthcare providers, its revenue and profitability may decline and it may incur losses.
• The company reviews and audits the care delivery, recordkeeping and billing processes of its operating subsidiaries.
• The company is subject to litigation, which is commonplace in its industry, which could result in significant legal costs and large settlement amounts or damage awards, and its self-insurance programs may expose it to significant and unexpected costs and losses.
• The company relies significantly on information technology, and any failure, inadequacy or interruption of that technology could harm its ability to effectively operate its business.
• The company may be unable to complete future facility or business acquisitions at attractive prices or at all, which may adversely affect its revenue; it may also elect to dispose of underperforming or nonstrategic operating subsidiaries, which would decrease its revenue.
• Because the company leases the majority of its facilities, it is subject to risks associated with leased real property, including risks relating to lease termination, lease extensions and special charges, any of which could have an adverse effect on its business, financial condition and results of operations.
• The company operates in a highly regulated industry with stringent regulatory compliance obligations, and is subject to extensive and complex laws and government regulations.
• The company has broad discretion in how it may use the net proceeds from this offering, and it may not use them effectively.
• The company's founders, Jason Murray and Mark Hancock, will continue to have substantial control over it and will hold a substantial portion of its outstanding common stock following this offering, and their interests may conflict, or appear to conflict, with the company's interests and the interests of other stockholders.
• The company will be a controlled company under the corporate governance rules of the New York Stock Exchange and intend to rely on exemptions from certain corporate governance requirements, including the requirements that within one year of the completion of this offering it have a board that is composed of majority of independent directors and have a nominating and corporate governance committee that is composed entirely of independent directors.
• Affiliates of Citigroup Global Markets Inc., J.P. Morgan Securities LLC, Truist Securities, Inc., RBC Capital Markets, LLC, Regions Securities LLC and KeyBanc Capital Markets Inc., each an underwriter in this offering, will each receive at least 5% of the net proceeds of this offering and may have an interest in this offering beyond customary underwriting discounts and commissions.

Future Outlook

The company anticipates that available acquisition opportunities will enable it to further penetrate its reach into its nine existing states and to enter new states in the future.

Industry Context

The announcement highlights PACS Group's position in the growing skilled nursing facility industry, which is experiencing increasing demand due to an aging population and a shift towards cost-efficient care settings. The company's focus on higher-value short-term transitional care aligns with industry trends.

Comparison to Industry Standards

• The document states that PACS Group's average QM Star rating across all its facilities was 4.1 Stars as of December 31, 2023, compared to the industry average of 3.6 Stars.
• The document states that PACS Group's average occupancy rate across its Mature facilities was 93% for the year ended December 31, 2023, compared to the industry average of 76%.

Related Party Transactions

• The document mentions a Consulting and Strategic Advisory Services Agreement with Helios Consulting, LLC, owned by Jason Murray and Mark Hancock, which was terminated on December 31, 2023.
• The document mentions subscription agreements with Messrs. Murray and Hancock, pursuant to which Messrs. Murray and Hancock each purchased 64,361,693 shares of our common stock for a purchase price of $10.00, or $0.001 per share, in a private placement concurrent with our incorporation in the State of Delaware and in anticipation of effecting our reorganization on June 30, 2023.

Stakeholder Impact

• Existing stockholders will experience dilution due to the issuance of new shares.
• New investors will have an opportunity to invest in a leading post-acute healthcare company.
• The company's ability to repay debt and fund future growth will be enhanced by the IPO proceeds.

Next Steps

• The company awaits approval to list its common stock on the New York Stock Exchange under the symbol PACS.
• The underwriters expect to deliver the shares of common stock to purchasers on or about , 2024.

Key Dates

Keywords

IPO, initial public offering, PACS Group, skilled nursing facilities, healthcare, NYSE, common stock, registration statement, S-1, post-acute care, Medicare, Medicaid